Overview

SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
This is an open label, phase Ib Study of SHR-1701 in patients with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
Phase:
Phase 1
Details
Lead Sponsor:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Albumin-Bound Paclitaxel
Cisplatin
Gemcitabine
Paclitaxel